Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of hesperidin in preparation of medicament for preventing and/or treating pulmonary fibrosis diseases

A technology of pulmonary fibrosis and hesperidin, applied in the field of hesperidin, can solve the problems that there are no research reports on the prevention and treatment of pulmonary fibrosis by hesperidin

Inactive Publication Date: 2015-09-16
HENAN UNIV OF CHINESE MEDICINE
View PDF2 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, there is no relevant research report on the prevention and treatment of pulmonary fibrosis by hesperidin

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of hesperidin in preparation of medicament for preventing and/or treating pulmonary fibrosis diseases
  • Application of hesperidin in preparation of medicament for preventing and/or treating pulmonary fibrosis diseases
  • Application of hesperidin in preparation of medicament for preventing and/or treating pulmonary fibrosis diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0045] Take 50g of hesperidin, 80g of starch and 20g of dextrin, first mix the various materials evenly, and pass through a 120-mesh sieve; then add an appropriate amount of 80% ethanol according to the conventional soft material preparation method to prepare a soft material, and pass the obtained soft material through a 20-mesh sieve , the obtained wet granules are placed in an oven, dried at 60-70°C for 1 hour, and granulated with an 18-mesh sieve after drying; after granulated, 5 g of sodium carboxymethyl starch and 5 g of magnesium stearate are added and mixed to make 1000 tablets. Tablets contain hesperidin 50mg. Oral 2-3 times a day, 50mg each time, is used for patients with stable chronic obstructive pulmonary disease to prevent the occurrence of pulmonary fibrosis.

Embodiment 2

[0047] In terms of mass percentage, the pharmaceutical composition with hesperidin as the main component of the present invention consists of 15% hesperidin, 5% tanshinone, 77% mannitol, 2.5% hypromellose and 0.5% magnesium stearate; First, weigh various raw materials according to the ratio of various raw materials, mix the various raw materials and pass through a 60-mesh sieve, then add ethanol with a mass percentage of 75% to moisten, prepare a soft material, extrude and granulate with a 40-mesh screen, The obtained wet granules were dried at a constant temperature of 40° C. for 3 hours, and then an appropriate amount of magnesium stearate was added according to a conventional method for sizing to obtain hesperidin granules. Each bag contains 60mg hesperidin and 40mg tanshinone, take 1 bag each time orally, 3 times a day, 2 months as a course of treatment, for patients with long-term asthma, to prevent the occurrence of pulmonary fibrosis.

Embodiment 3

[0049] The prescription of hesperidin enteric-coated soft capsule material of the present invention is gelatin: glycerin: water=1:1:2 (mass ratio), the content prescription of self-microemulsion soft capsule is: " isopropyl myristate:polyester Oxyethylene ether (40) hydrogenated castor oil (Cremophor RH40): polyethylene glycol 400 (PEG400): hesperidin = 1:4:4:1 (mass ratio)". According to the prescription of the above-mentioned soft capsule material and the prescription of the contents, the soft capsule is prepared according to the conventional soft capsule preparation method; sealed and sterilized. Orally take 100mg each time, 3 times a day, a course of treatment for 2 months, for the prevention and treatment of pulmonary fibrosis.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of hesperidin in preparation of a medicament for preventing and / or treating pulmonary fibrosis diseases. By virtue of experimental verification, the hesperidin can achieve an effect of preventing and treating pulmonary fibrosis by inhibiting lung fibroblast proliferation, inhibiting epithelium-mesenchyme conversion of alveolar epithelial cells and inhibiting lung fibroblast activation, so that the hesperidin can achieve a new application in preparation of the medicament for preventing and / or treating the pulmonary fibrosis diseases. The application relates to various medicament dosage forms such as capsules, drop pills, aerosol preparations, spraying agents, tablets, granules and injections prepared from the hesperidin. Moreover, the application also relates to a composition, which is formed by taking the hesperidin as a main component, for preventing and treating the pulmonary fibrosis.

Description

1. Technical field: [0001] The present invention relates to a use of hesperidin, in particular to a use of hesperidin in the preparation of medicines for preventing and / or treating pulmonary fibrosis. 2. Background technology: [0002] Pulmonary fibrosis (PF) is a common pathological change and final outcome of various diffuse interstitial lung diseases. The main clinical manifestation is progressive dyspnea, and eventually the patient dies due to dyspnea. Excessive accumulation of collagen, elastic fibers, and protein sugars in the extracellular matrix (ECM) is its characteristic histopathological change. At present, it is considered that the proliferation and activation of fibroblasts is the main reason for the formation and accumulation of ECM, and the mesenchymal transition of alveolar epithelial cells and the proliferation of fibroblasts are the main sources of fibroblasts. Under the action of harmful stimuli, cytokines, etc., fibroblasts are activated and secrete a la...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61P11/00
Inventor 任周新陈玉龙吴兆宇冯素香周悌强
Owner HENAN UNIV OF CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com